Edge Computing und Industrie 4.0. Anwendungsbereiche in der Schweizer Fertigungsindustrie

Durch die industrielle, digitale Transformation, insbesondere durch die Vernetzung von Fertigungsanlagen, wird zusehends eine sehr große Datenmenge in der Schweizer Fertigungsindustrie generiert. Viele Daten bleiben dabei lokal (oft) ungenutzt oder werden über weite Transportwege an zentrale Rechenzentren zur Analyse gesendet. Vor diesem Hintergrund stellt sich die Frage, wie Daten so genutzt werden können, dass lange Transportwege entfallen und zeitgleich, durch die Verarbeitung dieser Daten, Wissen generiert werden kann. Dieser Beitrag liefert erste Antworten auf der Basis von empirischen Erkenntnissen, welche durch Befragungen von Anbietern, Beratungsunternehmen und Fertigungsunternehmen im Bereich Edge Computing durchgeführt wurden. Dabei liefert die vorliegende Studie Erkenntnisse in den Bereichen technisches Verständnis, Geschäftsmodelle und Anwendungsszenarien sowie praktische Umsetzungen im Sinne von Pilotierungen und Rollouts als Proof of Concept

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Closing the pressure gap in x-ray photoelectron spectroscopy by membrane hydrogenation

Comprehensive studies of gas-solid reactions require the in-situ interaction of the gas at a pressure beyond the operating pressure of ultrahigh vacuum (UHV) X-ray photoelectron spectroscopy (XPS). The recent progress of near ambient pressure XPS allows to dose gases to the sample up to a pressure of 20 mbar. The present work describes an alternative to this experimental challenge, with a focus on H-2 as the interacting gas. Instead of exposing the sample under investigation to gaseous hydrogen, the sample is in contact with a hydrogen permeation membrane, through which hydrogen is transported from the outside to the sample as atomic hydrogen. Thereby, we can reach local hydrogen concentrations at the sample inside an UHV chamber, which is equipped with surface science tools, and this corresponds to a hydrogen pressure up to 1 bar without affecting the sensitivity or energy resolution of the spectrometer. This experimental approach is validated by two examples, that is, the reduction of a catalyst precursor for CO2 hydrogenation and the hydrogenation of a water reduction catalyst for photocatalytic H-2 production, but it opens the possibility of the new in situ characterisation of energy materials and catalysts. (C) 2015 AIP Publishing LLC

Closing the pressure gap in x-ray photoelectron spectroscopy by membrane hydrogenation

Comprehensive studies of gas-solid reactions require the in-situ interaction of the gas at a pressure beyond the operating pressure of ultrahigh vacuum (UHV) X-ray photoelectron spectroscopy (XPS). The recent progress of near ambient pressure XPS allows to dose gases to the sample up to a pressure of 20 mbar. The present work describes an alternative to this experimental challenge, with a focus on H2 as the interacting gas. Instead of exposing the sample under investigation to gaseous hydrogen, the sample is in contact with a hydrogen permeation membrane, through which hydrogen is transported from the outside to the sample as atomic hydrogen. Thereby, we can reach local hydrogen concentrations at the sample inside an UHV chamber, which is equipped with surface science tools, and this corresponds to a hydrogen pressure up to 1 bar without affecting the sensitivity or energy resolution of the spectrometer. This experimental approach is validated by two examples, that is, the reduction of a catalyst precursor for CO2 hydrogenation and the hydrogenation of a water reduction catalyst for photocatalytic H2 production, but it opens the possibility of the new in situ characterisation of energy materials and catalysts

Cobalt complexes of tetradentate, bipyridine-based macrocycles: their structures, properties and photocatalytic proton reduction

Complexes with purely pyridine-based macrocycles are rarely studied in photo(electro)catalysis. We synthesized and investigated macrocycles, in which two 2,2′-bipyridine (bpy) units are linked twice by two cyano-methylene groups, to yield the basic tetradentate, bipyridine based ligand framework (pyr). The protons in the bridges were substituted to obtain derivatives with one (pyr-alk) or two (pyr-alk2) alkyl-chains, respectively. We present the crystal structures of the mono-pentylated and the cis-dibutylated ligands. The corresponding CoII complexes [CoII(OH2)2(pyr)], [CoIIBr(HOMe)(pyr-bu)], [CoIIBr2(cis-pyr-bu2)] and [CoIIBr2(trans-pyr-bu2)] were prepared, their physico-chemical properties elucidated and their crystal structures determined. X-ray analyses revealed for the latter three complexes distorted octahedral coordination and a fairly planar {CoII(pyr)} macrocyclic scaffold. The axial bromides in [CoIIBr(HOMe)(pyr-bu)], [CoIIBr2(cis-pyr-bu2)] and [CoIIBr2(trans-pyr-bu2)] are weakly bound and dissociate upon dissolution in water. While the alkylated complexes are paramagnetic and feature CoII d7 high spin configurations, the unsubstituted complex [CoII(OH2)2(pyr)] displays a rare CoII low spin configuration. The electronic ground states of [CoIIBr2(cis-pyr-bu2)] and [CoIIBr2(trans-pyr-bu2)] are similar, as evident from the almost identical UV/vis spectra. Electrochemical analyses show redox-non-innocent ligand frameworks. All complexes are highly robust and efficient H+ reducing catalysts. In the presence of [Ru(bpy)3]Cl2 as a photosensitizer and TCEP/NaHasc as a sacrificial electron donor and shuttle, turnover numbers (TONs, H2/Co) up to 22 000 were achieved

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score–matched models. Results: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9–3.6], 4.0 [95% CI, 3.6–4.5], and 5.5 [95% CI, 5.0–6.1] events per 100 patient-years in strata 35–<50, and ≤35 mg/dL, respectively). Compared with propensity score–matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol but not vice versa. Conclusions: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.gov; Unique identifier: NCT01663402.URL: https://www